Chief Operating Officer

Mike has spent over 16 years engineering nanoparticles for various applications in technology and medicine. Dr. Bruckman obtained his Ph.D. in organic chemistry from the University at South Carolina and received additional training in Biomedical Engineering and medical device commercialization (CWRU). During this time, Mike researched plant viral nanoparticles (VNP) for a variety of applications: diagnosing atherosclerosis (MRI), drug delivery (cancer), VOC gas sensing, cell growth, and optical metamaterials (cloaking devices). Two years prior to joining Haima, Mike lead the commercialization of a saliva glucose sensor for diabetics at the technology development startup company, NanoBio Systems. 

Christa Pawlowski, PHd


Co-founder and Chief Scientific Officer

Christa has over a decade of experience conducting research related to platelet biology and platelet-inspired approaches in nanomedicine.  Christa received her PhD in Biomedical Engineering from Case Western Reserve University. As a graduate student and postdoctoral scholar in Dr. Sen Gupta's laboratory, she was lead researcher responsible for the design, fabrication and evaluation of the hemostatic capabilities (both in vitro and in vivo) of the SynthoPlate technology.

Anirban Sen Gupta, Phd


Co-founder and Chief Scientific Advisor

Anirban is a Professor in Biomedical Engineering at Case Western Reserve University. Anirban received his PhD in Chemical Engineering from the University of Akron and has 10+ years experience in engineering of platelet-mimetic particles with ~15 peer-reviewed articles in the area.



Junior Engineer

Norman has his Master’s in medical physiology from CWRU. He joined the Sen Gupta lab in 2017 to work on hemostatic drug delivery and the translational aspect of SynthoPlate. He recently joined Haima Therapeutics to further assist in commercialization of SynthoPlate.



Research Intern

Lauren is pursuing her Master’s of Public Health at CWRU with a focus on global health and disease burden. She has spent the last 3 years studying the pathophysiology underlying Type II Diabetes Mellitus and its comorbidities in Dr. John Kirwan’s lab at Lerner Research Institute. Training in a translational research lab sparked an interest in exploring commercialization of therapeutics. Recently, she joined the Haima team to learn how to navigate the process of developing a nano-therapeutic from the bench to the bedside.


Research Intern

Kara is pursuing her Master’s of Public Health at CWRU. She joined the Sen Gupta lab in 2017 and Haima in 2018.